Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome.
CONCLUSION: IST has a hematologic improvement response rate in the range of other therapies approved for lower risk MDS. High risk IPSS-R, poor karyotype, and treatment after 2 years from diagnosis have unfavorable response trend. ATG with CSA has higher response than ATG alone. First-line ATG or after lenalidomide had better response trend compared to third-line therapy or azacitidine therapy.
PMID: 27521323 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Haider M, Al Ali N, Padron E, Epling-Burnette P, Lancet J, List A, Komrokji R Tags: Clin Lymphoma Myeloma Leuk Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Databases & Libraries | Health | Hematology | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Restasis | Revlimid